April 5 (Reuters) - The U.S. Food and drug

Administration on Friday allowed use of Bristol-Myers Squibb ( BMY )

and 2seventybio's cell therapy Abecma in less

severely affected patients with a type of blood cancer.

The health regulator is also reviewing another cancer cell

therapy, Carvykti, from Johnson & Johnson ( JNJ ) and its

partner Legend Biotech ( LEGN ) for use in less severely

affected patients.